| Indication . | N = 440 (%) . |
|---|---|
| Developing asymmetry or global asymmetry without prior comparison, intermediate risk, and inconclusive findings on diagnostic mammography and US | 209 (47.5) |
| Multiple low-suspicion masses with variable features (often in the setting of dense breast tissue, intermediate risk, and inconclusive findings on diagnostic mammography and US) | 105 (23.9) |
| Multiple bilateral low-suspicion regional calcifications without definite mass or dominant suspicious grouping to optimize targeting for biopsy | 40 (9.1) |
| Dense breast tissue, high anxiety, intermediate risk, complex baseline | 25 (5.7) |
| Suspicion following nonconcordant biopsy | 13 (3.0) |
| Outside referral, high clinical concern despite negative imaging findings | 14 (3.2) |
| Concern for radiologic-pathologic discordance and/or possible sampling error | 11 (2.5) |
| Extent of disease in the setting of a new cancer, MRI contraindicated | 7 (1.6) |
| Family history of breast cancer, high risk | 6 (1.4) |
| Known breast cancer, follow-up to therapy | 4 (0.9) |
| Concerning changes too close to an implant to enable image-guided biopsy | 3 (0.7) |
| Unusually high risk of bleeding from biopsy | 3 (0.7) |
| Indication . | N = 440 (%) . |
|---|---|
| Developing asymmetry or global asymmetry without prior comparison, intermediate risk, and inconclusive findings on diagnostic mammography and US | 209 (47.5) |
| Multiple low-suspicion masses with variable features (often in the setting of dense breast tissue, intermediate risk, and inconclusive findings on diagnostic mammography and US) | 105 (23.9) |
| Multiple bilateral low-suspicion regional calcifications without definite mass or dominant suspicious grouping to optimize targeting for biopsy | 40 (9.1) |
| Dense breast tissue, high anxiety, intermediate risk, complex baseline | 25 (5.7) |
| Suspicion following nonconcordant biopsy | 13 (3.0) |
| Outside referral, high clinical concern despite negative imaging findings | 14 (3.2) |
| Concern for radiologic-pathologic discordance and/or possible sampling error | 11 (2.5) |
| Extent of disease in the setting of a new cancer, MRI contraindicated | 7 (1.6) |
| Family history of breast cancer, high risk | 6 (1.4) |
| Known breast cancer, follow-up to therapy | 4 (0.9) |
| Concerning changes too close to an implant to enable image-guided biopsy | 3 (0.7) |
| Unusually high risk of bleeding from biopsy | 3 (0.7) |
| Indication . | N = 440 (%) . |
|---|---|
| Developing asymmetry or global asymmetry without prior comparison, intermediate risk, and inconclusive findings on diagnostic mammography and US | 209 (47.5) |
| Multiple low-suspicion masses with variable features (often in the setting of dense breast tissue, intermediate risk, and inconclusive findings on diagnostic mammography and US) | 105 (23.9) |
| Multiple bilateral low-suspicion regional calcifications without definite mass or dominant suspicious grouping to optimize targeting for biopsy | 40 (9.1) |
| Dense breast tissue, high anxiety, intermediate risk, complex baseline | 25 (5.7) |
| Suspicion following nonconcordant biopsy | 13 (3.0) |
| Outside referral, high clinical concern despite negative imaging findings | 14 (3.2) |
| Concern for radiologic-pathologic discordance and/or possible sampling error | 11 (2.5) |
| Extent of disease in the setting of a new cancer, MRI contraindicated | 7 (1.6) |
| Family history of breast cancer, high risk | 6 (1.4) |
| Known breast cancer, follow-up to therapy | 4 (0.9) |
| Concerning changes too close to an implant to enable image-guided biopsy | 3 (0.7) |
| Unusually high risk of bleeding from biopsy | 3 (0.7) |
| Indication . | N = 440 (%) . |
|---|---|
| Developing asymmetry or global asymmetry without prior comparison, intermediate risk, and inconclusive findings on diagnostic mammography and US | 209 (47.5) |
| Multiple low-suspicion masses with variable features (often in the setting of dense breast tissue, intermediate risk, and inconclusive findings on diagnostic mammography and US) | 105 (23.9) |
| Multiple bilateral low-suspicion regional calcifications without definite mass or dominant suspicious grouping to optimize targeting for biopsy | 40 (9.1) |
| Dense breast tissue, high anxiety, intermediate risk, complex baseline | 25 (5.7) |
| Suspicion following nonconcordant biopsy | 13 (3.0) |
| Outside referral, high clinical concern despite negative imaging findings | 14 (3.2) |
| Concern for radiologic-pathologic discordance and/or possible sampling error | 11 (2.5) |
| Extent of disease in the setting of a new cancer, MRI contraindicated | 7 (1.6) |
| Family history of breast cancer, high risk | 6 (1.4) |
| Known breast cancer, follow-up to therapy | 4 (0.9) |
| Concerning changes too close to an implant to enable image-guided biopsy | 3 (0.7) |
| Unusually high risk of bleeding from biopsy | 3 (0.7) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
